Secured $76.8 Million Verdict on Behalf of Health Insurers in Direct Action Alleging Unlawful Monopolization of Prescription Drugs

August 29, 2017

In re: Lorazepam & Clorazepate Antitrust Litigation, 99-mc-00276 (D.D.C.)

Robins Kaplan secured a $76.8 million jury verdict on behalf of three health insurers that allegedly overpaid for prescription drugs because of a branded manufacturer’s anticompetitive exclusion of generic competition through the restriction of the generics’ supply of active pharmaceutical ingredients.

Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.

Similar Results

Back to Top